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H. Pylori deemed as one of the causes of gastric pathologies (mainly chronic superficial gastritis, chronic atrophic 
gastritis, gastroduodenal ulcer, etc.) which can progress to gastric atrophy and cancer of the stomach. Although still not well known pathogenesis and Physiopathology of 
damage by H. Pylori, has recently attracted attention histological framework of these diseases. In particular, mast cells are found frequently and in a number of 
pathologies such increased at a significant correlation what makes think that mast cells have a manifestly impact in pathogenesis of these pathologies. We wanted to 
verify whether any correlations exist between HP positivity, type of gastritis and presence of mast cells. We examined 90 bioptic fragments of gastric mucosa obtained 
by diagnostic oesophagogastroduodenoscopy. The study population consisted of 22 patients with chronic superficial gastritis and 8 with chronic  atrophic gastritis (20 
males and 10 females). HP detection was performed on Giemsa-stained  preparations. Mast cell detection was performed on Giemsa- and PAS-stained preparations. 
Sixty-eight percent of chronic superficial gastritis cases were found to be HP-positive and  mast cell were present in 87% of these and absent in 13%. In chronic atrophic 
gastritis cases 50% were HP-positive and mast cell were present in 50% and absent in the rest. On the basis of our data a significant correlation was found (86%) 
between HP-positivity and presence of mast cells in the inflammatory gastric mucosa.  
 
 
 Introduction 
 
 Since 1983 when Warren and Marshall showed presence of gastric antral mucosa HP in patients with type B antral 
gastritis and / or peptic ulcer, literature data for such correlation have been risen. 
 Observations according to Giemsa-stained preparations for the HP research has long shown in infiltration of chronic 
gastritis, variable presence of mast cells (MTC). 
 Mast cells eosine-hematoxiline-stained present several characteristics: they have a diameter about 8-15μ and a central 
densely nucleus, round or oval, cytoplasm filled with anfofil  granules  that many mediators of inflammation such as histamine, 
leukocyte chemiotactic factors, PAF, heparin, hyaluronic acid and mucopolisacaride, nonsulphide acid, whose role is not yet clearly 
defined.  Mast cells can interfere with enzymes in the inflammation single complex mechanism of gastric mucosa caused by HP. 
 
 Materials and methods 
 
 We have examined 300 fragments of gastric mucosa biopsy obtained through oesophagogastroduodenoscopy Diagnostic 
Center Hospital "Dr. Xhaferr Kongoli "Elbasan in dyspeptic patients. Histological examination was conducted at the Service of 
Pathology of the University Hospital Center "Mother Theresa". The study population comprised 22 cases with chronic gastritis 
surface (GCS) and chronic atrophic gastritis 8 with (GCA), of which 20 males and 10 females. Age average growth rate is 55, of 
which 57 for males (with age limits from 30 to 76) and 52 for females (with age limits from 20 to 85). 
 
 
 N. of cases Age average Age limits 
Males 20 57 30-76 
Females 10 52 20-85 
Total 3 55  
 
 The distribution of cases by sex and age 
 The incidence of pathology shows a first peak growth in the fifth decade of life (29.5%) and a second peak in the seventh 
decade of life (27%) unrelated to sex. Search for HP took in stained preparations by Giemsa and were examined. Search of mast 
cells was conducted in stained preparations by Giemsa and PAS. 
 
 Results 
 
 In the case of GCS 68% (15 cases) resulted positive in the search for HP, in which mast cells were present (HP +/MTC +) 
in 87% of cases (13 cases) and missing (HP +/MTC-) in 13% of cases (2 cases). At  32% (7 cases) resulted negative in the search 
for HP and mast cells were present (HP+/MCT-) in 14% of cases (1 case) and missing (HP-/MTC-) at 86% (6 cases).  Also in the 
case of GCS is present the mast cells infiltration (HP +/MCT + and HP-/MCT +) in 64% of cases (14 cases) and misses (HP +/MCT- 
and HP-/MCT-) to 36% (8 cases). 
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 In the case of GCA 50% (4 cases) resulted positive in the search for HP and mast cells were present (HP +/MCT +) in 
50% of cases (2 cases) and missing (HP +/MTC-) in the remaining 50%. In 4 cases with negative GCA match HP mast cells were 
present (HP-/MCT +) in only one case (25%) and missing (HP-/MCT-) in 3 other cases (75%). GCA has therefore matching (HP 
+/MCT + and HP-/MTC-) to 63% (5 cases) and doesn’t match to 37% (3 cases). In the entire population as a whole is seen a 
matching in 86% of cases and no matching in 14% of cases. 
 
 
 
 Percentage and distribution of positivity for HP and mast cells 
 
 Discussion 
 
 Helicobacter pylori was discovered by Warren and Marshall in 1982. They showed that this bacterium (then called 
Campylobacter Pylori) was able to live at acid pH of stomach and cause gastritis. Subsequent studies showed that the bacterium, 
later called Helicobacter pylori (H. pylori) is the main agent of gastric pathological manifestations. H. pylori is a gram-negative 
flagella bacterium, with dimensions of 3.5-0.5 nm, ribosomal subunit RNA consisting of a specific nucleotide sequence, which 
infects about half of the world population, whose main deposit is the human stomach. Gastric colonization by H. pylori usually 
occurs during the first decade of life, and in the absence of antibiotic treatment the infection continues for a lifetime.  
 
 H. pylori has unique microbiological features that allows it to survive in conditions such as stomach acid environment. 
Transmission of infection occurs mainly through oro-fecal route and oro-oral, particularly through contaminated food and water. 
Once penetrating the stomach, H. pylori turns gastric urea fluid in NH3 and CO2 thanks to ureasa. NH3 produced from urea lysis 
actively pumped into extracellular space contributing to the creation of an alkaline pH which allows the survival of bacteria in the 
acidic environment of gastric juice. After colonization in the stomach, H. pylori contributes to the induction of an inflammatory 
response, profound changes in gastric homeostasis regarding the regulation of acid secretion and regulation of cell cycle and 
programmed death (apoptosis) of gastric epithelial cells. These changes will then be partly responsible for the evolution of the 
infection. 
 
 Regulation of gastric secretion mainly achieved in gastric antrum level where D cells which produce somatostatin restrain 
gastric G-manufacturing cells, gastrointestinal hormone which stimulates the secretion of hydrochloric acid by the stomach. In the 
case of H. pylori infection, antrum inflammation is associated with a reduction and ban D cells production. For this reason, G cells, 
not inhibited by D cell somatostatin, produce more gastrin.                     
 
 In general, all H. pylori positive subjects are hypergastrinemic. Gastrin secreted by G cells enters the circulation and 
reaches the end of the gastric corpus region, rich in parietal cells, whose surface are located the main receptors responsible for the 
regulation of gastric secretion, including those for gastrin. Gastric interaction and its receptor activate HK- ATP-dependent pump 
(proton pump) and the production of  hydrochloric acid. If the mucosa of the region is intact, hypergastrinemia forced by infection 
will cause in susceptible subjects, or by increasing the amount of parietal cells, or the presence of parietal cells more sensitive to 
stimulus gastrinemic, an acid hyper secretion which can later lead to the development of duodenal peptic ulcers. In subjects where 
H. pylori infection has caused the inflammation in gastric corpus terminus region, with atrophy of acid-secreting mucosa, the 
hypergastrinemia will be associated with hypo-aklorhidria, a prerequisite for gastric cancer. H. pylori infection diagnosis is based 
on invasive tests (oesophagogastroduodenoscopy, endoscopy, and biopsy) and non-invasive tests. 
 
Invasive tests are: 
1 Quick ureasa test, which consists in placing a sample taken for biopsy stomach, containing urea and a pH indicator which 
changes color from yellow to red in the case of alkaline from forming bacterial ureasa CO2 and NH3. The test has a sensitivity of 
90%;  
2. Histological examination of stomach material biopsy after coloring with eosine -hematoxiline or Giemsa. Histological 
HP+ HP- 
 HP
+/MTC+  HP+/MTC- HP-/MTC+  HP-
/MTC- 
% 
 N. of cases %  N. of cases % N. of cases %  N. of cases  
GCS 13 87  2 13 1 14  6 86 
No total   15     7   
%   68     32   
           
GCA 2 50  2 50 1 25  3 75 
Nototal   4     4   
%   50     50   
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examination is the gold standard in the diagnosis of H. pylori infection with a specific sensitivity around 99%. (Our study reference 
refers to this method) 
3. Bacterial culture that allows, when positive, to test the sensitivity of bacteria isolated to specific antibiotics commonly used to 
eradicate them. The test has high specificity (100%), but the sensitivity ranging from 77% - 92%. 
 
Non-invasive tests that do not require the execution of endoscopy are:  
 
1. Serology, by examining the anti H. pylori IgG antibodies. 
This test, although it has high sensitivity and specificity, does not distinguish between active infections from healed infection 
spontaneously or due to therapy. 
2. 13C-Urea Breath Test (UBT 13C). This test, which uses ureasa bacterial activity, based on oral administration of 13C labeled urea 
and evaluation by the amount of 13C spectrometry present in exhaled breath. 
Sensitivity and specificity of this test is approximately 98%. 
3. HPSA (H. pylori Stool antigen). The test consists in the identification of an antigen ELISA H. pylori in faeces.  
Sensitivity and specificity are similar to those of UBT 13C. 
A recent survey, conducted by Gianni Marone and Amato de Paulis, has identified another cell that interferes in the action 
mechanism of Helicobacter pylori, which opens the possibility to understand and block the mechanism that causes chronic gastritis 
and ulcers, a disease that can degenerate into cancer of the stomach. Identified cell is an immune cell, unnoticed up to now, that 
results to be a valuable ally of Helicobacter pylori. According to them the bacterium doesn’t penetrate deeply into the tissues of the 
stomach, but remains localized in the surface layer of mucous. In its place, what penetrates deeply is a protein secreted by bacteria 
called Hp (2.20). Once placed in stomach tissue, protein affects basophiles, which are identified as involved in the ulcer and 
gastritis. In basophiles were identified two receptors (FPRL1 and FPRL2) related to protein produced by H. pylori. So, there is 
another immune system cell involved in the diseases that lead to the appearance of tumors of the stomach. According to this data, 
blocking receptors in the cell becomes possible to prevent the progression of gastric cancer. It also paves the way for a new 
treatment of gastritis and peptic ulcer. From the analysis of our population shows a significant correlation (86%) between HP 
positivity research and mast cells presence of inflammatory infiltrate in the gastric mucosa. At 14% of the corresponding cases can’ 
not be explained by changes subsequent to the environment such as hipchlorhidria gastric, intestinal metaplasia, overlapping 
competitive bacterial flora or by taking medication that has not been possible to verify. In conclusion, the registered results of the 
correlation HP / MTC suggest a major role of mast cells within gastric disease HP correlates. Literature data seem to confirm this. 
 
References  
1. Marshall BJ and Warren JR. Unidentified curved bacilli inb the stomach of patients with gastritis and peptic ulceration. Lancet 
1984; 1(8390):1311-1315. 
2. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of 
Campylobacter pylori. Lancet 1988; 2(8626-8627): 1437-1442 
3. Ricci V, Zarrilli R, Romano M. Voyage of Helicobacter pylori in human stomach: Odyssey of a bacterium. Digest Liver Dis 
2002; 34: 2-8. 
4. Peek RM, Jr and Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37. 
5. Amieva MR and El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134:306-323 
6. Romano M, V. Ricci V, R. Zarrilli R. Helicobacter pylori-related gastric carcinogenesis - implications for chemoprevention. Nat 
Clin Pract Gastroenterol Hepatol 2006; 3: 622-632. 
7. Romano M and Cuomo A. Pharmacotherapy of Helicobacter pylori-associated gastritis. In: A. Guglietta Ed. Pharmacotherapy of 
Gastrointestinal Inflammation. Birkhauser Verlag AG, Basel 2003, page 1-16. 
8. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the 
Maastricht III Consensus Report. Gut 2007; 56: 772-81. 
9. Romano M, M.R. Iovene MR, Russo MI, et al. Failure of first line eradication treatment significantly increases prevalence of 
anti-microbial resistant helicobacter pylori clinical isolates. J Clin Pathol 2008; 61: 1112-1115. 
10. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug-therapy for Helicobacter pylori eradication. A 
randomized trial. Ann Intern Med 2007; 146: 556-563 
11. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric 
cancer ? Ann Intern Med 2009; 151: 121-128. 
12. Cover TL and Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 1863-1873 
13. Dorer MS, Talarico S, Salama NR. Helicobacter pylori’s unconventional role in health and disease. PLOS Pathogens 2009. 
14.Hazell SL. Lee A. Compilobacter pyloris and gastritis; association with intracellular spaces and adaption to an environment  of 
mucus as important factors in colonization of gastric epithelium. J infect 1986; 153. 
15. Kurose I, Granger DN et bp, Helicobacter pylori-induced microvascular protein leakage in rats; role of neutrophils, mast-cells 
and platelets. Gastroenterology 1994; 107; 70-9. 
16.Dobrilla G. peptic ulcer, functional dyspepsia, helicobacter pylori: on the topic of their correlation and therapeutic strategies.  
Page | 65  
Volume 4, issue 4, 2015  e-ISSN: 1857-8187   p-ISSN: 1857-8179                                                                                                                     Case study 
